LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28(a)


Company Announcement no. 34/2007                                                

To: OMX Nordic Exchange			Hørsholm, Denmark, December 27, 2007 

  LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act,  
                                 Section 28(a)                                  

Hørsholm, Denmark, December 27, 2007; Pursuant to the Danish Securities Trading 
Act, Section 28(a), LifeCycle Pharma A/S (OMX: LCP) is required on a daily      
basis, to make public transactions in LifeCycle Pharma shares and related       
securities by persons discharging managerial responsibilities and persons /     
companies closely associated with these.                                        

--------------------------------------------------------------------------------
| Name                                 | Thomas Dyrberg                        |
--------------------------------------------------------------------------------
| Reason for reporting                 | Member of the Board of Directors      |
--------------------------------------------------------------------------------
| Issuer and ID code/ISIN              | LifeCycle Pharma A/S / DK0060048148   |
--------------------------------------------------------------------------------
| Type of transaction                  | Purchase of shares                    |
--------------------------------------------------------------------------------
| Date of transaction                  | December 21, 2007                     |
--------------------------------------------------------------------------------
| Relevant market                      | OMX Nordic Exchange                   |
--------------------------------------------------------------------------------
| Number of traded securities          | 5,000                                 |
--------------------------------------------------------------------------------
| Market value                         | DKK 181,000                           |
--------------------------------------------------------------------------------


About LifeCycle Pharma A/S (“LCP”)                                              
LCP is an emerging specialty pharmaceuticals company that, through innovative   
technologies, is able to rapidly develop a portfolio of differentiated products 
to meet the unique needs of key therapeutic markets and patient populations.    
This includes products for immunosuppression, specifically organ                
transplantation, and to combat certain cardiovascular diseases.  By using its   
unique and patented delivery technology, MeltDose®, LCP is able to develop drugs
with enhanced absorption and thereby increased bioavailability. Currently, the  
Company has a diversified near- and medium-term pipeline, including a product   
ready for US commercialization, five product candidates in clinical trials and  
three in preclinical stages of development. LCP is listed on the OMX Nordic     
Exchange under the trading symbol (OMX: LCP). For further information, please   
visit www.lcpharma.com.                                                         

Contact:                                                                        
LifeCycle Pharma A/S                                                            
Michael Wolff Jensen, EVP and CFO
+45 4074-6244; MWJ@lcpharma.com                  

or                                                                              

Francesca M. DeMartino                                                          
Director, Investor Relations & Corporate Communications                         
(917) 747-4938; FDM@lcpharma.com

Attachments

20071227 - lifecycle pharma - report pursuant to the danish securities trading act section 28_a_.pdf